

Arun J Sanyal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1764590/publications.pdf>

Version: 2024-02-01

384
papers

74,557
citations

1614

105
h-index

584

262
g-index

432
all docs

432
docs citations

432
times ranked

43148
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.	7.3	8,518
2	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67, 328-357.	7.3	4,738
3	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55, 2005-2023.	7.3	2,935
4	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2010, 362, 1675-1685.	27.0	2,718
5	Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 2018, 24, 908-922.	30.7	2,392
6	Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-1192.	1.3	1,846
7	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	13.7	1,840
8	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
9	Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 2007, 46, 922-938.	7.3	1,673
10	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018, 67, 123-133.	7.3	1,474
11	The global NAFLD epidemic. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 686-690.	17.8	1,426
12	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
13	Rifaximin Treatment in Hepatic Encephalopathy. New England Journal of Medicine, 2010, 362, 1071-1081.	27.0	1,116
14	A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology, 2007, 46, 1081-1090.	7.3	1,096
15	Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2009, 7, 1104-1112.	4.4	1,065
16	Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003, 37, 1286-1292.	7.3	984
17	AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 1705-1725.	1.3	961
18	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA - Journal of the American Medical Association, 2011, 305, 1659.	7.4	926

#	ARTICLE	IF	CITATIONS
19	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	1.3	847
20	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	27.0	833
21	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 2184-2196.	13.7	818
22	Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2013, 145, 574-582.e1.	1.3	795
23	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	3.7	685
24	Endpoints and clinical trial design for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 54, 344-353.	7.3	617
25	Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. <i>Hepatology</i> , 2008, 48, 1810-1820.	7.3	589
26	A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. <i>Gastroenterology</i> , 2008, 134, 1360-1368.	1.3	588
27	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	7.3	528
28	The plasma lipidomic signature of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009, 50, 1827-1838.	7.3	521
29	Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2008, 134, 568-576.	1.3	518
30	Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2012, 15, 665-674.	16.2	517
31	Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. <i>Hepatology</i> , 2006, 43, 682-689.	7.3	458
32	Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. <i>Gut</i> , 2015, 64, 800-812.	12.1	458
33	The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. <i>Oncologist</i> , 2010, 15, 14-22.	3.7	437
34	The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , 2003, 124, 634-641.	1.3	424
35	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 77-85.	7.3	412
36	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1559-1569.	27.0	406

#	ARTICLE	IF	CITATIONS
37	Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. <i>Hepatology</i> , 2004, 40, 802-810.	7.3	400
38	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 913-924.	7.3	397
39	A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1107-1115.	4.4	388
40	Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. <i>Gastroenterology</i> , 2016, 150, 785-790.	1.3	387
41	Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1049-1061.	3.4	374
42	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet</i> , The, 2018, 392, 2705-2717.	13.7	374
43	A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. <i>Journal of Hepatology</i> , 2016, 65, 579-588.	3.7	371
44	Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. <i>Nature Medicine</i> , 2001, 7, 827-832.	30.7	363
45	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012, 107, 811-826.	0.4	359
46	Past, present and future perspectives in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 377-386.	17.8	357
47	Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 285-300.	4.7	352
48	Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. <i>Gut</i> , 2017, 66, 180-190.	12.1	342
49	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	4.4	322
50	Portal Hypertension and Its Complications. <i>Gastroenterology</i> , 2008, 134, 1715-1728.	1.3	303
51	Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. <i>Journal of Hepatology</i> , 2016, 65, 1140-1147.	3.7	296
52	The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. <i>Gastroenterology</i> , 1997, 112, 889-898.	1.3	293
53	Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseasesâ€™U.S. Food and Drug Administration Joint Workshop. <i>Hepatology</i> , 2015, 61, 1392-1405.	7.3	288
54	Management of NAFLD: a stage-based approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 196-205.	17.8	287

#	ARTICLE	IF	CITATIONS
55	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine, 2021, 385, 1547-1558.	27.0	284
56	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 221-235.	3.6	278
57	Preclinical models of non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 68, 230-237.	3.7	268
58	The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology, 2018, 67, 534-548.	7.3	266
59	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology, 2021, 73, 1194-1198.	7.3	266
60	No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology, 2014, 147, 377-384.e1.	1.3	260
61	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 1140-1153.	1.3	253
62	Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology, 1996, 111, 138-146.	1.3	250
63	Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. Journal of Hepatology, 2020, 73, 1322-1332.	3.7	235
64	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. New England Journal of Medicine, 2021, 384, 818-828.	27.0	235
65	Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2012, 57, 384-391.	3.7	233
66	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	5.9	230
67	Current efforts and trends in the treatment of NASH. Journal of Hepatology, 2015, 62, S65-S75.	3.7	228
68	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, 2020, 72, 892-905.	7.3	227
69	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019, 70, 1913-1927.	7.3	226
70	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016, 150, 1579-1589.e2.	1.3	225
71	Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. Journal of Hepatology, 2011, 55, 315-321.	3.7	216
72	Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study*1. Hepatology, 1994, 20, 46-55.	7.3	212

#	ARTICLE	IF	CITATIONS
73	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 153, 753-761.	1.3	209
74	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.	1.3	203
75	17 β -Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 1504-1519.	7.3	200
76	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144.	7.3	192
77	Therapies in nonalcoholic steatohepatitis (<sc>NASH</sc>). <i>Liver International</i> , 2017, 37, 97-103.	3.9	188
78	Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1352-1355.	8.6	186
79	Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 46-53.	1.7	182
80	Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1390-1397.e2.	4.4	180
81	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365.	1.8	178
82	Therapeutic pipeline in nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 373-392.	17.8	173
83	Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β^2 cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 600-605.	2.1	172
84	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020, 72, 816-827.	3.7	165
85	Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1000-1008.e3.	4.4	164
86	Vitamin <sc>E</sc> and changes in serum alanine aminotransferase levels in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 134-143.	3.7	163
87	Mechanisms of Obesity-Induced Gastrointestinal Neoplasia. <i>Gastroenterology</i> , 2014, 146, 357-373.	1.3	157
88	Stomal complications of gastric bypass: incidence and outcome of therapy. <i>American Journal of Gastroenterology</i> , 1992, 87, 1165-9.	0.4	147
89	Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. <i>Hepatology</i> , 2013, 58, 1644-1654.	7.3	146
90	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	4.4	145

#	ARTICLE	IF	CITATIONS
91	The role of thiazolidinediones in non-alcoholic steatohepatitis â€” A systematic review and meta analysis. Journal of Hepatology, 2011, 55, 1383-1390.	3.7	144
92	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. Journal of Hepatology, 2020, 72, 613-626.	3.7	143
93	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 970-985.	8.1	142
94	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology, 2012, 55, 419-428.	7.3	141
95	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary Clinical Trials, 2009, 30, 88-96.	1.8	140
96	Nonâ€”alcoholic fatty liver disease (<sc>NAFLD</sc>) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1630-1634.	4.4	137
97	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Eventsâ€”Prospective Study. Clinical Gastroenterology and Hepatology, 2020, 18, 2324-2331.e4.	4.4	136
98	The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology, 2018, 67, 1284-1302.	7.3	134
99	Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism, 2020, 31, 35-45.	16.2	130
100	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
101	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology, 2019, 71, 823-833.	3.7	120
102	The hematologic consequences of transjugular intrahepatic portosystemic shunt. Hepatology, 1996, 23, 32-39.	7.3	118
103	Metabolomicâ€”based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology Communications, 2018, 2, 807-820.	4.3	117
104	Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncology, The, 2022, 23, 521-530.	10.7	116
105	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Alimentary Pharmacology and Therapeutics, 2019, 50, 193-203.	3.7	112
106	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 865-878.	3.7	111
107	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107
108	An Openâ€”Label, Doseâ€”Escalation Study to Assess the Safety and Efficacy of ILâ€”22 Agonist Fâ€”652 in Patients With Alcoholâ€”Associated Hepatitis. Hepatology, 2020, 72, 441-453.	7.3	107

#	ARTICLE	IF	CITATIONS
109	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. <i>Hepatology</i> , 2019, 70, 522-531.	7.3	106
110	Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 12541.	3.3	106
111	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	1.8	105
112	<scp>Nonalcoholic fatty liver disease</scp> as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1069-1083.	4.4	104
113	Abnormalities of Lipid Metabolism in Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2008, 28, 351-359.	3.6	100
114	Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet β Cells to Promote Glucose Homeostasis. <i>Journal of Biological Chemistry</i> , 2016, 291, 6626-6640.	3.4	100
115	Inhibition of 11 β -HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 406-416.	11.4	98
116	Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. <i>JCI Insight</i> , 2016, 1, e90954.	5.0	98
117	Non-alcoholic fatty liver disease in lean individuals. <i>JHEP Reports</i> , 2019, 1, 329-341.	4.9	98
118	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , 2021, 27, 1825-1835.	30.7	98
119	Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0136822.	2.5	96
120	The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 855-864.	1.0	94
121	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.8	92
122	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatrics</i> , 2017, 187, 141-146.e1.	1.8	91
123	Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the <scp>OT</scp> and <scp>REVERSE</scp> randomised clinical studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1390-1402.	3.7	90
124	An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 619-629.e7.	4.4	90
125	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 25-33.	3.7	88
126	Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC- β pathway and modulated by endogenous H ₂ S. <i>Frontiers in Physiology</i> , 2014, 5, 420.	2.8	86

#	ARTICLE	IF	CITATIONS
127	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	7.3	86
128	Evaluation and management of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2005, 42, S2-S12.	3.7	84
129	Role of aramchol in steatohepatitis and fibrosis in mice. <i>Hepatology Communications</i> , 2017, 1, 911-927.	4.3	84
130	Pathogenesis of NASH: the Impact of Multiple Pathways. <i>Current Hepatology Reports</i> , 2018, 17, 350-360.	0.9	84
131	Lipotoxicity in NASH. <i>Journal of Hepatology</i> , 2012, 56, 291-293.	3.7	83
132	Drug-Induced Steatohepatitis. <i>Clinics in Liver Disease</i> , 2013, 17, 533-546.	2.1	81
133	Drug-induced fatty liver disease: An overview of pathogenesis and management. <i>Annals of Hepatology</i> , 2015, 14, 789-806.	1.5	81
134	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889.	1.8	80
135	Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis. <i>Gastroenterology</i> , 2013, 145, 1271-1279.e3.	1.3	79
136	Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1857-1867.	4.5	79
137	Multicenter Validation of Association Between Decline in MRIâ€PDF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	7.3	79
138	Role of gut microbiota in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G84-G98.	3.4	78
139	Lean NAFLD: an Underrecognized Outlier. <i>Current Hepatology Reports</i> , 2016, 15, 134-139.	0.9	76
140	Toward More Accurate Nomenclature for Fatty Liver Diseases. <i>Gastroenterology</i> , 2019, 157, 590-593.	1.3	75
141	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	3.7	74
142	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. <i>Hepatology</i> , 2019, 70, 1424-1436.	7.3	73
143	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2019, 156, 88-95.e5.	1.3	73
144	Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity. <i>Hepatology</i> , 2020, 72, 271-286.	7.3	73

#	ARTICLE	IF	CITATIONS
145	Preserved hemostatic status in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 65, 980-987.	3.7	72
146	The PPAR α/β Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 9330.	3.3	72
147	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	21.4	68
148	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. <i>Hepatology</i> , 1994, 19, 933-940.	7.3	66
149	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	3.7	66
150	Breakthroughs in therapies for NASH and remaining challenges. <i>Journal of Hepatology</i> , 2022, 76, 1263-1278.	3.7	66
151	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.4	65
152	Effects of Rare Microbiome Taxa Filtering on Statistical Analysis. <i>Frontiers in Microbiology</i> , 2020, 11, 607325.	3.5	65
153	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.	7.3	64
154	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 2565.	3.3	63
155	Transjugular Intrahepatic Portosystemic Shunt. <i>Clinics in Liver Disease</i> , 2014, 18, 853-876.	2.1	59
156	A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2462-2473.e10.	4.4	59
157	The Commensal Microbe <i>Veillonella</i> as a Marker for Response to an FGF19 Analog in NASH. <i>Hepatology</i> , 2021, 73, 126-143.	7.3	58
158	Development of pseudointima and stenosis after transjugular intrahepatic portosystemic shunts: Characterization of cell phenotype and function. <i>Hepatology</i> , 1998, 28, 22-32.	7.3	57
159	C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. <i>Hepatology</i> , 2018, 67, 1441-1457.	7.3	57
160	Genetics, diagnostics and therapeutic advances in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 65-66.	17.8	56
161	Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 649-662.	9.4	56
162	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021, 73, 571-585.	7.3	56

#	ARTICLE	IF	CITATIONS
163	A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 3-14.	4.4	56
164	Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. <i>Liver International</i> , 2015, 35, 936-943.	3.9	55
165	Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 477-485.e5.	4.4	55
166	Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. <i>World Journal of Gastroenterology</i> , 2018, 24, 1269-1277.	3.3	55
167	Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 266-272.e1.	4.4	53
168	An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. <i>Scientific Reports</i> , 2018, 8, 12414.	3.3	53
169	Burden of Disease due to Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 1-23.	2.2	53
170	Current management of non-alcoholic steatohepatitis. <i>Liver International</i> , 2020, 40, 89-95.	3.9	52
171	Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1831-1838.e3.	4.4	50
172	The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2017, 7, 17193.	3.3	50
173	Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. <i>Gastroenterology</i> , 2020, 159, 1731-1751.e10.	1.3	49
174	Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 483-496.	8.9	49
175	Drug-induced steatohepatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 193-204.	3.3	47
176	Nonalcoholic steatohepatitis is associated with a state of betaine insufficiency. <i>Liver International</i> , 2017, 37, 611-619.	3.9	47
177	Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	3.9	47
178	Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G66-G76.	3.4	45
179	The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study. <i>Liver Transplantation</i> , 2015, 21, 1123-1132.	2.4	45
180	The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.	3.7	45

#	ARTICLE	IF	CITATIONS
181	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	7.3	45
182	Regional differences in sorafenib-treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study. <i>Liver International</i> , 2016, 36, 1196-1205.	3.9	44
183	The multifaceted role of natriuretic peptides in metabolic syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 826-835.	5.6	44
184	Dual-photon microscopy-based quantitation of fibrosis-related parameters (q α FP) to model disease progression in steatohepatitis. <i>Hepatology</i> , 2017, 65, 1891-1903.	7.3	43
185	Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2021, 8, 691696.	2.6	43
186	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 575843.	3.5	43
187	Reply:. <i>Hepatology</i> , 2007, 46, 1312-1312.	7.3	42
188	Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G794-G803.	3.4	42
189	Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2017, 77, 3306-3316.	0.9	42
190	Future therapy for non-alcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 56-63.	3.9	42
191	Harnessing Muscle“Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 592373.	3.5	42
192	Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis. <i>Cell Death and Differentiation</i> , 2014, 21, 1303-1312.	11.2	41
193	A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2670-2672.	4.4	41
194	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	4.4	41
195	Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. <i>Journal of Hepatology</i> , 2022, 77, 1399-1409.	3.7	41
196	Review article: non-alcoholic fatty liver disease and hepatitis C - risk factors and clinical implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 48-51.	3.7	40
197	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019, 70, e5.	3.7	39
198	Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. <i>Hepatology</i> , 2022, 75, 1647-1661.	7.3	39

#	ARTICLE	IF	CITATIONS
199	The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 565-574.	8.9	39
200	Performance of noninvasive models of fibrosis in predicting mild to moderate fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 572-579.	3.9	38
201	Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. <i>Contemporary Clinical Trials</i> , 2017, 61, 33-38.	1.8	38
202	FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice. <i>Journal of Lipid Research</i> , 2019, 60, 1311-1322.	4.2	38
203	SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH. <i>Hepatology Communications</i> , 2021, 5, 760-773.	4.3	38
204	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Contemporary Clinical Trials</i> , 2021, 104, 106335.	1.8	38
205	Recent advances in understanding and managing non-alcoholic fatty liver disease. <i>F1000Research</i> , 2018, 7, 720.	1.6	37
206	Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis. <i>Hepatology</i> , 2021, 73, 1290-1306.	7.3	37
207	Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. <i>Gut</i> , 2022, 71, 254-264.	12.1	37
208	Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2451-2461.e3.	4.4	37
209	A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. <i>Transactions of the American Clinical and Climatological Association</i> , 2015, 126, 271-88.	0.5	37
210	A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1520-1534.	7.3	36
211	Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. <i>JHEP Reports</i> , 2021, 3, 100255.	4.9	36
212	Liver transplantation significantly improves global functioning and cerebral processing. <i>Liver Transplantation</i> , 2016, 22, 1379-1390.	2.4	35
213	A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH). <i>Hepatology</i> , 2017, 66, 466-480.	7.3	35
214	New drugs for NASH. <i>Liver International</i> , 2021, 41, 112-118.	3.9	34
215	Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18885.	0.4	33
216	The Worsening Profile of Alcoholic Hepatitis in the United States. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1295-1303.	2.4	33

#	ARTICLE	IF	CITATIONS
217	Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. <i>Patient</i> , 2021, 14, 533-543.	2.7	33
218	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. <i>Nature Medicine</i> , 2022, 28, 430-432.	30.7	33
219	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 277-292.	2.1	32
220	Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00105.	2.4	32
221	Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. <i>JHEP Reports</i> , 2019, 1, 429-437.	4.9	31
222	Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. <i>JHEP Reports</i> , 2020, 2, 100099.	4.9	30
223	Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. <i>Hepatology</i> , 2022, 76, 1811-1824.	7.3	30
224	Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 488-493.	2.7	29
225	Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 50-58.	4.4	29
226	Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study. <i>Hepatology</i> , 2017, 66, 575-590.	7.3	29
227	Treatment of HCV in the Department of Corrections in the Era of Oral Medications. <i>Journal of Correctional Health Care</i> , 2018, 24, 127-136.	0.5	29
228	Small Dense Lowâ€Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. <i>Hepatology</i> , 2019, 70, 98-107.	7.3	29
229	The Fibrosis-4 Index Is Associated With Need for Mechanical Ventilation and 30-Day Mortality in Patients Admitted With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2020, 222, 1794-1797.	4.0	29
230	Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 45-54.e6.	4.4	29
231	Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. <i>Liver International</i> , 2011, 31, 23-28.	3.9	28
232	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. <i>Toxicology in Vitro</i> , 2017, 39, 93-103.	2.4	28
233	Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs. <i>Scientific Reports</i> , 2018, 8, 7967.	3.3	28
234	Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. <i>Toxicological Sciences</i> , 2019, 170, 273-282.	3.1	28

#	ARTICLE	IF	CITATIONS
235	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 702-713.	3.7	28
236	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1456-1466.	3.4	28
237	Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 623-633.	3.7	28
238	Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma) in pts with liver dysfunction.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4126-4126.	1.6	28
239	Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 313, C305-C313.	4.6	27
240	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300.	3.7	27
241	Alcohol Abstinence Does Not Fully Reverse Abnormalities of Mucosal-Associated Invariant T Cells in the Blood of Patients With Alcoholic Hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00052.	2.5	26
242	Treatment of fulminant hepatic failure with intravenous prostaglandin E1. <i>Liver Transplantation</i> , 1998, 4, 424-431.	1.8	25
243	Early Trends in Cystatin C and Outcomes in Patients with Cirrhosis and Acute Kidney Injury. <i>International Journal of Nephrology</i> , 2014, 2014, 1-8.	1.3	25
244	Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis. <i>Gastroenterology</i> , 2015, 149, 4-9.	1.3	25
245	The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2018, 22, 121-132.	2.1	25
246	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	1.8	25
247	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. <i>Hepatology</i> , 2021, 74, 3146-3160.	7.3	25
248	Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. <i>Gastroenterology</i> , 2017, 153, 621-625.e7.	1.3	24
249	Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2018, 12, 6-16.	4.2	24
250	Suppression of IGF binding protein-1 by palmitate promotes hepatic inflammatory responses. <i>FASEB Journal</i> , 2016, 30, 4071-4082.	0.5	23
251	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 903-913.	2.4	23
252	New drugs for non-alcoholic steatohepatitis. <i>Liver International</i> , 2020, 40, 96-101.	3.9	23

#	ARTICLE	IF	CITATIONS
253	Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1513-1526.	7.3	23
254	Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. <i>Hepatology International</i> , 2022, 16, 269-281.	4.2	23
255	Nonendoscopic Management Strategies for Acute Esophagogastric Variceal Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 819-833.	2.2	21
256	Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players. <i>Current Pathobiology Reports</i> , 2014, 2, 109-116.	3.4	21
257	Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese. <i>Journal of Lipid Research</i> , 2016, 57, 1017-1028.	4.2	21
258	Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?. <i>BMC Medicine</i> , 2018, 16, 148.	5.5	21
259	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. <i>Hepatology Communications</i> , 2021, 5, 938-946.	4.3	21
260	Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1345-1351.	3.7	20
261	Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20
262	End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 11-13.	1.3	19
263	Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-9.	1.9	19
264	SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR. <i>Journal of Hepatology</i> , 2019, 70, e796-e797.	3.7	19
265	Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model. <i>FASEB Journal</i> , 2020, 34, 7773-7785.	0.5	19
266	Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 636637.	2.6	19
267	Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. <i>Cell Reports</i> , 2022, 38, 110454.	6.4	19
268	A model of acute kidney injury in mice with cirrhosis and infection. <i>Liver International</i> , 2016, 36, 865-873.	3.9	18
269	Acute Alcoholic Hepatitis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017, 1, 37-48.	2.4	18
270	Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. <i>Hepatology Communications</i> , 2018, 2, 29-34.	4.3	18

#	ARTICLE	IF	CITATIONS
271	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 515-532.	4.8	18
272	Coagulation Disorders and Bleeding in Liver Disease: Future Directions. <i>Clinics in Liver Disease</i> , 2009, 13, 155-157.	2.1	17
273	Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2016, 150, 1723-1727.	1.3	17
274	Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2021, 12, 665987.	3.5	17
275	Long term changes in liver histology following treatment of chronic hepatitis C virus. <i>Annals of Hepatology</i> , 2014, 13, 340-9.	1.5	17
276	A new preclinical model of western dietâ€induced progression of nonâ€alcoholic steatohepatitis to hepatocellular carcinoma. <i>FASEB Journal</i> , 2022, 36, .	0.5	17
277	Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 2000-2006.	2.4	16
278	Farnesoid X Receptor Agonism, Acetylâ€Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model. <i>Hepatology Communications</i> , 2020, 4, 109-125.	4.3	16
279	A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. <i>Hepatology International</i> , 2021, 15, 1196-1206.	4.2	16
280	Validation of Noninvasive Methods for Detecting Hepatic Steatosis in Patients With Human Immunodeficiency Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 402-405.	4.4	15
281	Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. <i>American Journal of Surgery</i> , 2017, 213, 688-695.	1.8	15
282	Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcoholâ€Associated Hepatitis. <i>Hepatology</i> , 2021, 74, 2436-2451.	7.3	15
283	Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 166-173.	1.3	15
284	Metaâ€analysis: analysis of mechanistic pathways in the treatment of <scp>nonâ€alcoholic</scp> steatohepatitis. Evidence from a Bayesian network <scp>metaâ€analysis</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	3.7	15
285	An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1263-1269.	1.5	13
286	Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 750-758.	2.2	13
287	Longitudinal studies can identify distinct inflammatory cytokines associated with the inhibition or progression of liver cancer. <i>Liver International</i> , 2020, 40, 468-472.	3.9	13
288	NAFLD-related HCC. <i>Advances in Cancer Research</i> , 2021, 149, 143-169.	5.0	13

#	ARTICLE	IF	CITATIONS
289	Reply to: “Procoagulant imbalance in patients with non-alcoholic fatty liver disease” Journal of Hepatology, 2017, 66, 250-251.	3.7	13
290	Posttraumatic Stress Disorder in Patients with Heavy Alcohol Consumption and Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2018, 42, 1933-1938.	2.4	12
291	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceutical Medicine, 2019, 33, 451-463.	1.9	12
292	Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 2132-2133.	4.4	12
293	Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS ONE, 2020, 15, e0236353.	2.5	12
294	Safety, Tolerability, and Physiological Effects of AXA1665, a Novel Composition of Amino Acids, in Subjects With Child “Pugh A and B Cirrhosis. Clinical and Translational Gastroenterology, 2020, 11, e00222.	2.5	12
295	Emerging roles of AATF: Checkpoint signaling and beyond. Journal of Cellular Physiology, 2021, 236, 3383-3395.	4.1	12
296	NAFLD: The evolving landscape. Journal of Hepatology, 2018, 68, 227-229.	3.7	11
297	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. Digestive Diseases and Sciences, 2021, 66, 263-272.	2.3	11
298	The use of cell free DNA in the diagnosis of HCC. Hepatoma Research, 2019, 2019, .	1.5	11
299	Minimizing ascites. Postgraduate Medicine, 2001, 109, 91-103.	2.0	10
300	Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovascular Endocrinology, 2017, 6, 62-72.	0.8	10
301	Liver biopsy in the real world “reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	3.7	10
302	Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. JHEP Reports, 2022, 4, 100392.	4.9	10
303	Development of Alcohol “Associated Hepatitis Is Associated With Specific Changes in Gut “Modified Bile Acids. Hepatology Communications, 2022, 6, 1073-1089.	4.3	10
304	Premicellar taurocholate avidly binds ferrous (Fe++) iron: a potential physiologic role for bile salts in iron absorption. Translational Research, 1990, 116, 76-86.	2.3	10
305	Deletion or inhibition of SphK1 mitigates fulminant hepatic failure by suppressing TNF “dependent inflammation and apoptosis. FASEB Journal, 2021, 35, e21415.	0.5	9
306	Fibrosis “4 Predicts the Need for Mechanical Ventilation in a National Multiethnic Cohort of Corona Virus Disease 2019. Hepatology Communications, 2021, 5, 1605-1615.	4.3	9

#	ARTICLE	IF	CITATIONS
307	Randomized placebo-controlled trial of losartan for pediatric NAFLD. <i>Hepatology</i> , 2022, 76, 429-444.	7.3	9
308	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	3.7	9
309	Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 570-579.	3.7	9
310	Use of desirability functions to evaluate health status in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 665-671.	3.7	8
311	LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension. <i>Journal of Hepatology</i> , 2019, 70, e127.	3.7	8
312	LPCN 1144 Resolves NAFLD in Hypogonadal Males. <i>Hepatology Communications</i> , 2020, 4, 1430-1440.	4.3	8
313	Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 709-719.	2.4	8
314	Recent advances in understanding/management of non-alcoholic steatohepatitis. <i>F1000prime Reports</i> , 2015, 7, 28.	5.9	8
315	Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1401-1409.	3.9	8
316	Novel therapeutic targets for steatohepatitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, S46-S50.	1.5	7
317	Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1695-1697.	1.3	7
318	Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2202-2204.	4.4	7
319	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. <i>Hepatology International</i> , 2014, 8, 517-526.	4.2	6
320	KEAP the balance between life and death. <i>Molecular and Cellular Oncology</i> , 2015, 2, e968065.	0.7	6
321	Clinical characteristics and outcomes of mild to moderate alcoholic hepatitis. <i>GastroHep</i> , 2019, 1, 161-165.	0.6	6
322	Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 619-636.	3.7	6
323	Persistent Hyperactivation of Endothelial Cells in Patients with Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1075-1087.	2.4	6
324	Myths and Mysteries About Staging Hepatic Fibrosis by Fibroscan. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 780-782.	4.4	5

#	ARTICLE	IF	CITATIONS
325	Lovastatin may reduce the risk of erectile dysfunction following radiation therapy for prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 1500-1502.	1.8	5
326	Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. <i>Thrombosis Research</i> , 2017, 150, 41-43.	1.7	5
327	Blood Biomarkers of Intestinal Epithelium Damage Regenerating Islet-1-derived Protein 3 and Trefoil Factor 3 Are Persistently Elevated in Patients with Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 720-731.	2.4	5
328	Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. <i>Diabetes and Metabolism</i> , 2022, 48, 101281.	2.9	5
329	Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet. <i>Epigenetics</i> , 2022, 17, 1462-1476.	2.7	5
330	The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2013, 7, 309-312.	4.2	4
331	Treatment of refractory ascites. <i>Clinical Liver Disease</i> , 2013, 2, 140-142.	2.1	4
332	Trials and Tribulations in Drug Development for Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2104-2105.	4.4	4
333	Treatment of NASH: What Helps Beyond Weight Loss?. <i>American Journal of Gastroenterology</i> , 2017, 112, 821-824.	0.4	4
334	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. <i>Hepatology</i> , 1994, 19, 933-940.	7.3	4
335	The hematologic consequences of transjugular intrahepatic portosystemic shunt. <i>Hepatology</i> , 1996, 23, 32-39.	7.3	4
336	Dissecting the Balance Between Metabolic and Oncogenic Functions of Astrocyte-Elevated Gene-1/Metadherin. <i>Hepatology Communications</i> , 2022, 6, 561-575.	4.3	4
337	The management of the cirrhotic patient after transjugular intrahepatic portosystemic shunt. <i>Seminars in Gastrointestinal Disease</i> , 1997, 8, 188-99.	0.8	4
338	Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. <i>Methods in Molecular Biology</i> , 2022, 2455, 19-30.	0.9	4
339	Evidence that bile salts are important for iron absorption. <i>American Journal of Physiology - Renal Physiology</i> , 1994, 266, G318-G323.	3.4	3
340	An integrated view of liver injury and disease progression in nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013, 7, 800-805.	4.2	3
341	Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. <i>Journal of Investigative Medicine</i> , 2018, 66, 661-668.	1.6	3
342	PS-111-Six month interim results of MSDC-0602 K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). <i>Journal of Hepatology</i> , 2019, 70, e70.	3.7	3

#	ARTICLE	IF	CITATIONS
343	<p>Verified Hepatorenal Syndrome Reversal As A Robust Multi-Component Primary End Point: The CONFIRM Study Trial Design</p>. Open Access Journal of Clinical Trials, 2019, Volume 11, 67-73.	1.5	3
344	Risk Prediction of Nosocomial and Posthospital Discharge Infections in Alcoholâ€Associated Hepatitis. Hepatology Communications, 2021, 5, 2096-2103.	4.3	3
345	Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome. Journal of Clinical Lipidology, 2021, 15, 805-813.	1.5	3
346	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcoholâ€associated hepatitis. Hepatology, 2022, 75, 968-982.	7.3	3
347	Healthâ€related quality of life is dynamic in alcoholic hepatitis and responds to improvement in liver disease and reduced alcohol consumption. Alcoholism: Clinical and Experimental Research, 2022, 46, 252-261.	2.4	3
348	MEGX: from bench to bedside. American Journal of Gastroenterology, 1992, 87, 919-21.	0.4	3
349	TIPS: the new kid on the block. Hepatology, 1994, 20, 1092-5.	7.3	3
350	A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	1.4	3
351	Transjugular intrahepatic portosystemic shunt: An overview. Clinical Liver Disease, 2012, 1, 173-176.	2.1	2
352	Reply. Gastroenterology, 2015, 148, 262-263.	1.3	2
353	Transjugular intrahepatic portosystemic shunt for refractory ascites in patients with high model for endâ€stage liver disease scores. Clinical Liver Disease, 2016, 7, 84-87.	2.1	2
354	Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitusâ€authors' response. Gut, 2018, 67, 1372-1372.	12.1	2
355	SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS â‰¥ 4) and significant fibrosis (F â‰¥ 2) in patients at risk of NASH. Journal of Hepatology, 2019, 70, e770.	3.7	2
356	Changes in Serum Myostatin Levels in Alcoholic Hepatitis Correlate with Improvement in MELD. Digestive Diseases and Sciences, 2021, 66, 3062-3073.	2.3	2
357	Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC) Tj ETQq1 1 0.784314 rgBT /Ove status.. Journal of Clinical Oncology, 2012, 30, 282-282.	1.6	2
358	Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health. Clinical Liver Disease, 2022, 20, 48-51.	2.1	2
359	Hepatorenal syndrome. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S248-S252.	2.8	1
360	Preface. Clinics in Liver Disease, 2009, 13, xv.	2.1	1

#	ARTICLE	IF	CITATIONS
361	Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	1
362	The fibrosis benefit index for assessment of therapeutic benefit in non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 241-243.	8.1	1
363	Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?. <i>Clinical Liver Disease</i> , 2021, 17, 215-219.	2.1	1
364	A lipidomic analysis of nonalcoholic fatty liver disease. , 2007, 46, 1081.		1
365	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
366	Use of staging and scoring systems in hepatocellular carcinoma (HCC): Lessons from U.S. regional analysis of the GIDEON registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, 323-323.	1.6	1
367	The treatment of hepatic encephalopathy in the cirrhotic patient. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-12.	0.1	1
368	A simplified method for the isolation and culture of endothelial cells from pseudointima of transjugular intrahepatic portasystemic shunts. <i>Laboratory Investigation</i> , 1998, 78, 1469-70.	3.7	1
369	Advances and Evolving Concepts in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2012, 16, ix-x.	2.1	0
370	Refractory Ascites: How to Establish the Diagnosis and What Can Be Done?. <i>Current Hepatitis Reports</i> , 2014, 13, 50-59.	0.3	0
371	Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis â€“ Author's reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 550-551.	8.1	0
372	Reply. <i>Hepatology</i> , 2017, 66, 999-1000.	7.3	0
373	Clinical endpoints are necessary in the interim analysis of REGENERATE â€“ Authors' reply. <i>Lancet</i> , The, 2020, 396, 663-664.	13.7	0
374	Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, xiii-xiv.	2.2	0
375	Prevention of free fatty acids/high fat dietâ€“induced hepatic lipotoxicity by 18 Î² glycyrrhetic acid. <i>FASEB Journal</i> , 2008, 22, 1138.10.	0.5	0
376	Second interim analysis of Global Investigation of Therapeutic Decisions in Unresectable HCC and of its Treatment with Sorafenib (GIDEON): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14581-e14581.	1.6	0
377	Potential factors influencing initial sorafenib dose selection in hepatocellular carcinoma (HCC): U.S. regional analysis of GIDEON.. <i>Journal of Clinical Oncology</i> , 2014, 32, 304-304.	1.6	0
378	Regulation of pancreatic Î² cell function by GLPâ€“1 released from Î± cells in response to activation of TGR5 by bile acids. <i>FASEB Journal</i> , 2015, 29, LB656.	0.5	0

#	ARTICLE	IF	CITATIONS
379	Phase II study of lovastatin to prevent rectal injury from radiation therapy for prostate cancer.. Journal of Clinical Oncology, 2016, 34, 120-120.	1.6	0
380	Liver Biopsy. , 2020, , 349-354.		0
381	Genetics of Nonalcoholic Steatohepatitis. Gastroenterology and Hepatology, 2020, 16, 651-653.	0.1	0
382	Pharmacology of NASH. , 2021, , .		0
383	Reply. Hepatology, 2022, 76, E5-E6.	7.3	0
384	Letter: noninvasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> â€”not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0